相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cluster stability in the analysis of mass cytometry data
Rossella Melchiotti et al.
CYTOMETRY PART A (2017)
The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab
Julia K. Tietze et al.
EUROPEAN JOURNAL OF CANCER (2017)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens et al.
CLINICAL CANCER RESEARCH (2016)
A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma
Susan M. Hiniker et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Luisa Carbognin et al.
PLOS ONE (2015)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Automated identification of stratifying signatures in cellular subpopulations
Robert V. Bruggner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Normalization of mass cytometry data with bead standards
Rachel Finck et al.
CYTOMETRY PART A (2013)
viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
El-ad David Amir et al.
NATURE BIOTECHNOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Reversible Senescence in Human CD4+CD45RA+CD27- Memory T Cells
Diletta Di Mitri et al.
JOURNAL OF IMMUNOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
Sean C. Bendall et al.
SCIENCE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Regularization and variable selection via the elastic net
H Zou et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2005)
Macrophage inflammatory protein-1
M Maurer et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2004)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
